Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | DUT | P33316 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL578484 | 0.92 | KDM4E (0.53) | ALDH1A1KDM4EMAOBDRD2DRD4 | |
| SCHEMBL13196947 | 0.87 | KDM4E (0.42) | ALDH1A1KDM4EMAOBLMNASMN1; SMN2 | |
| SCHEMBL15831460 | 0.84 | DRD2 (0.44) | ALDH1A1DRD2DRD4DRD3DUT | |
| SCHEMBL5857320 | 0.84 | MEN1 (0.45) | ALDH1A1KDM4ELMNASMN1; SMN2MEN1 | |
| SCHEMBL31621061 | 0.83 | APP (0.42) | ALDH1A1KDM4EDUTSMN1; SMN2 | |
| SCHEMBL275331 | 0.83 | LTA4H (0.47) | DRD2DRD4DRD3DUTLMNA | |
| SCHEMBL27083521 | 0.83 | KDM4E (0.36) | ALDH1A1KDM4EMAOBDUT | |
| SCHEMBL15814847 | 0.83 | TDP1 (0.47) | ALDH1A1KDM4EMAOBDUTTSHR | |
| SCHEMBL30152184 | 0.82 | CHRNB2 (0.39) | ALDH1A1KDM4EDUT | |
| SCHEMBL18990452 | 0.82 | CHRNB2 (0.39) | ALDH1A1KDM4EDUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| CN-118878461-A | PD-1/PD-L1 inhibitors | 吉利德科学公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | C4 THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117580592-A | Compounds for targeting bruton's tyrosine kinase degradation | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2022235945-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4026835-A2 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3612525-B1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-10-21 | — | — | US | disclosed |
| EP-3612525-A1 | PD-1/PD-L1 INHIBITORS | Gilead Sciences, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| US-6251921-B1 | ADMINISTERING THROMBIN INHIBITING DIAMINE COMPOUND TO MAMMAL | ELI LILLY AND COMPANY | 2001-06-26 | — | — | US | disclosed |
| EP-0993300-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0980367-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | disclosed |
| US-6025382-A | Antithrombotic diamines | ELI LILLY AND COMPANY (US) | 2000-02-15 | — | — | US | disclosed |
| EP-0903583-A2 | Reduction in first slide bias and improved enzyme stability by incorporation of diaryl tellurides in the gravure layer of dry-film immunoassay elements | Ortho-Clinical Diagnostics, Inc. (US) | 1999-03-24 | — | — | EP | disclosed |
| WO-1998048798-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049161-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0747704-A2 | Immunoassay element containing a diaryl telluride compound to increase its stability | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1996-12-11 | — | — | EP | disclosed |
| EP-0732923-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS | Abbott Laboratories (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995020384-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323922-A1 | PD-1/PD-L1 INHIBITORS | CD274, PDCD1, PDCD1LG2 | ALDH1A1 104/4885KDM4E 1276/4885MAOB 2005/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | ALDH1A1 409/4885KDM4E 1970/4885MAOB 1633/4885 |
| US-20240287076-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | BTK, SYK, LYN | ALDH1A1 3476/4885KDM4E 772/4885MAOB 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.